Jazz Pharma to pay $145M to settle Xyrem antitrust class action; records Q1 charge

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Ireland subsidiary agrees to pay $145M lump sum to settle indirect Xyrem purchaser class action.
Company will record a pre-tax charge of approximately $145M in Q1 2025, funded by cash on hand.
Settlement remains subject to court approval; Jazz denies all alleged wrongdoing.
The settlement resolves the majority of claims in the multi-district litigation; additional settlements with remaining plaintiffs may be significant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.